CNTX
Context Therapeutics Inc.
Set alert
- YTD
- -87.14%
- 1 year
- -83.27%
- Open
- 0.203
- Prev close
- 0.2017
- Mkt cap
- 17.37M
- Vol
- 1.01M
- Avg vol
- 1.53M
- EPS
- -0.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1888
- High
- 0.203
- Forward P/E
- -3.38
- Beta
- 2.25
- Short ratio
- 2.79
- Inst. own
- 76.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.79
- 200-d avg
- 1.86
- 1y target
- 7.70
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
2 weeks ago zacks.com
New Strong Sell Stocks for October 15th
CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
2 weeks ago zacks.com
New Strong Sell Stocks for October 13th
ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
1 month ago globenewswire.com
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
2 months ago benzinga.com
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
-
2 months ago benzinga.com
Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses…
2 months ago globenewswire.com
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund…
3 months ago globenewswire.com
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
-
3 months ago benzinga.com
Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today
3 months ago globenewswire.com
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)…
-
4 months ago benzinga.com
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable…
4 months ago benzinga.com
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
-
4 months ago benzinga.com
Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapyCytokine Release Syndrome ("CRS")…
4 months ago globenewswire.com
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
4 months ago globenewswire.com
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago globenewswire.com
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
5 months ago globenewswire.com
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
-
5 months ago benzinga.com
Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of…
5 months ago globenewswire.com
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202…
-
7 months ago benzinga.com
Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
7 months ago globenewswire.com
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,…
7 months ago defenseworld.net
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat…
7 months ago defenseworld.net
Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)
Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target
Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.
-
7 months ago benzinga.com
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
-
7 months ago benzinga.com
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
7 months ago globenewswire.com
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash…
7 months ago globenewswire.com
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)…
7 months ago defenseworld.net
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology…
8 months ago defenseworld.net
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat…
8 months ago globenewswire.com
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
9 months ago benzinga.com
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
10 months ago benzinga.com
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
-
10 months ago benzinga.com
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
-
11 months ago benzinga.com
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
-
11 months ago benzinga.com
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses…
-
1 year ago benzinga.com
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
-
1 year ago benzinga.com
Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
1 year ago benzinga.com
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
-
1 year ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Context Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.